期刊文献+

滋阴保肝汤治疗肝硬化临床研究

Study on the Curative Effect of Ziyin Baogan Decoction in the Treatment of Liver Cirrhosis
下载PDF
导出
摘要 目的研究滋阴保肝汤治疗肝硬化的疗效。方法选择2017年3月-2018年12月收治的200例肝硬化患者,根据随机数字表法分为2组,每组100例。对照组应用双歧杆菌三联活菌散治疗,观察组应用滋阴保肝汤治疗。观察2组治疗6个月后的远期疗效及中医证候积分。结果观察组的总有效率(98%)高于对照组(96%),差异具有统计学意义(P<0.05);治疗6个月后,观察组的中医证候积分(15.42±1.14)分明显低于对照组(20.45±1.32)分,差异具有统计学意义(P<0.05)。结论滋阴保肝汤治疗肝硬化可有效改善患者临床症状,降低其中医证候积分,疗效显著,值得推广。 Objective To study the effect of Ziyin Baogan decoction on liver cirrhosis. Methods 200 patients with cirrhosis from March 2017 to December 2018 were divided into two groups according to the random number table method. The control group was treated with bifidobacterium trifidobacterium, and the observation group was treated with Ziyin Baogan decoction. The long-term efficacy and TCM syndrome scores were observed after 6 months of treatment. Results The total effective rate of the observation group(98%) was higher than that of the control group(96%), and the difference was statistically significant(P<0.05). After 6 months of treatment, TCM was observed in the observation group. The score of syndrome(15.42±1.14) was significantly lower than that of the control group(20.45±1.32)(P<0.05). Conclusion The application of Ziyin Baogan decoction in the treatment of liver cirrhosis can effectively improve the clinical symptoms and reduce the score of TCM syndromes, and has significant curative effect, which is worth popularizing.
作者 骆晓霞 LUO Xiaoxia(Department of Infection,People's Hospital of Shicheng,Jiangxi Province,Ganzhou 324700,China)
出处 《光明中医》 2020年第3期355-357,共3页 GUANGMING JOURNAL OF CHINESE MEDICINE
关键词 肝硬化 滋阴保肝汤 中医证候积分 Cirrhosis Ziyin Baogan decoction TCM syndrome score
  • 相关文献

参考文献6

二级参考文献71

  • 1马玉芳,龙一梅,李遇春.辛开苦降法探析[J].浙江中医杂志,2006,41(2):66-68. 被引量:14
  • 2陈灏珠.实用内科学[M].12版.北京:人民卫生出版社,2012:1576-1579.
  • 3HYI-IROGLOU P, SNOVER DC, ALVES V, et al. Beyond " cirrhosis" : a proposal from the International Liver Pathology Study Group[J]. Am J Clin Pathol, 2012, 137(1 ): 5 -9.
  • 4MANOLAKOPOULOS S, TRIANTOS C, THEODOROPOULOS J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg -negative chronic hepatitis B and significant portal hypertension [ J ]. J Hepatol, 2009, 51 (3): 468 -474.
  • 5MARCELLIN P, GANE E, BUTI M, et al. Regression of cir- rhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5 -year open -label follow -up study [J]. Lancet, 2013, 381(9865):468-475.
  • 6MORGAN TR, GHANY MG, KIM HY, et al. Outcome of sus- tained virological responders with histologically advanced chronic hepatitis C[J]. Hepatology, 2010, 52(3) : 833 -844.
  • 7CHARLTON MR, POCKROS P J, HARRISON SA. Impact of obesity on treatment of chronic hepatitis C[ J ]. Hepatology, 2006, 43(6) :1177 -1186.
  • 8CHOLONGITAS E, THEOCHARIDQU E, GOULIS J, et al. Re- view article: the extra -skeletal effects of vitamin D in chronic hepatitis C infection[J]. Aliment Pharmacol Ther, 2012, 35(6) : 634-646.
  • 9RAO GA, PANDYA PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hep- atitis C[J]. Gastroenterology, 2011, 140(1): 144-152.
  • 10RIPOLL C, GROSZMANN R J, GARCIA-TSAO G, et al. He- patic venous pressure gradient predicts development of hep- atocellular carcinoma independently of severity of cirrhosis [J]. J Hepatel, 2009, 50(5) : 923 -928.

共引文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部